Fusion Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Okay, we're going to get started on the next session. I'm Andrew Tsai -- hi, everyone -- senior biotech analyst here at Jefferies. And I'm joined by John Valliant, CEO of Fusion.
Welcome, John.
Thank you.
Questions & Answers
And I think we have 25 minutes for our fireside chat. So, John, to start -- maybe to begin, maybe give us a brief overview of Fusion and -- what is your differentiation versus some of the players out there, in your view? What can you do that others cannot? And then maybe talk about your news flow over the next six to 12 months.
Sure, Andrew. Happy to. Thanks for everyone joining.
So Fusion is focused on creating next-generation radiopharmaceuticals and, more specifically, targeted alpha therapies. So the general premise of the technology is to connect an alpha
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |